EU application 006864
Insulin aspart biosimilar developed by Applicant not yet named by EMA. Reference product NovoRapid (NovoLog in the United States).
Brands by market: Under evaluation by EMA since November 2025 · Commercial partner or holder: EU application
FDANot listed
EMAUnder review
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Not yet approved in any of the 7 markets
Connections
About EU application 006864
A second insulin aspart application began evaluation in Europe in November 2025 alongside the one above, and restarted in July 2026. The applicant will be named at opinion.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Application 006864
European Medicines Agency and European CommissionUnder reviewBrand
Application 006864
Holder or applicant
Applicant not yet named by EMA
Pathway
Centralised (Article 10(4))
Status
Under evaluation by the CHMP since Nov 2025; procedure restarted Jul 2026
Presentations
see SmPC
Remarks
Under CHMP evaluation since 2025-11-27; procedure restarted after questions 2026-07-20. Applicant not named in EMA's list.
Source
S019 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Chronology
- EMANov 2025CHMP evaluation started
Sources
S019EMA, applications for new human medicines under evaluation by the CHMP, August 2026 Primary (regulator)
Planning insulin aspart biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.